Chronic pain management is stuck in an old loop—opioids, short-acting therapies, and inconsistent results. Innocan Pharma is pushing for a different path. Their latest study, published in Frontiers in Pharmacology, offers early evidence that long-acting liposomal CBD (LPT-CBD) may deliver sustained relief with a strong safety profile.
This is more than another CBD headline. It’s a window into a potential non-opioid therapy designed for long-term, stable, predictable pain control.
A Closer Look at the Study
Innocan’s research explored how synthetic liposomal CBD behaves when injected subcutaneously every six weeks. The study followed two goats suffering from chronic, debilitating pain for ten months.
The approach was simple:
Consistent dosing → continuous monitoring → real-world quality-of-life assessments.
Key Findings at a Glance
- Stable CBD levels: Repeated LPT-CBD injections maintained steady CBD plasma concentrations with a clear slow-release profile.
- Strong tolerability: No adverse events were recorded across seven injections per subject.
- Liver-safe: Unlike repeated oral CBD intake in humans, LPT-CBD did not elevate liver enzymes, a key marker of liver stress.
- Real improvements: Pain relief, mobility, and overall quality of life improved and stayed consistent for the entire 10-month period.
- Practical dosing: A single injection every six weeks offered sustained therapeutic levels—making it easier for chronic pain patients to manage treatment.
Why This Matters for Future Therapies?
The study offers clinically translatable insights. LPT-CBD’s long-acting nature could make it a compelling alternative for chronic pain patients who need steady relief without daily dosing or opioid risks.
Professor Chezy Barenholz summarises it well:
“The sustained beneficial effects observed over 10 months support LPT-CBD as a chronic therapy with repeated monthly administrations.”
Dr. Eyal Kalo adds another critical point:
“Repeated injections did not elevate liver enzymes, unlike oral CBD. This strengthens the evidence of long-term safety.”
In other words—stable pain control, reduced dosing frequency, and a cleaner safety profile.
The Bigger Picture: Innocan’s Mission
Innocan continues to build solutions at the crossroads of biotechnology and wellness.
Pharmaceutical Focus
- Their liposome-based CBD platform enables precise dosing.
- It supports controlled, prolonged release, reducing the need for frequent administration.
- Designed specifically for non-opioid chronic pain management.
Wellness Segment
- Through its subsidiary BI Sky Global (60% owned), the company develops a wide range of self-care and beauty products.
- Focus remains on science-backed consumer wellness and digital-first distribution.
Final Takeaway
This early translational study marks an important milestone. LPT-CBD’s long-acting profile, combined with promising safety and efficacy signals, positions it as a potential next-generation therapy for chronic pain.
If future clinical results echo these findings, chronic pain management may soon have a smarter, safer, longer-lasting option.
